BioCentury
ARTICLE | Politics & Policy

First five agents selected for lung cancer initiative

November 8, 2013 1:53 AM UTC

The first five compounds that will be evaluated in the "master protocol" study for squamous cell lung cancer were disclosed on Thursday at the Conference on Clinical Cancer Research, which was co-hosted by Friends of Cancer Research and the Brookings Institution. The protocol -- a Phase II/III trial intended to provide data to support registration of new drugs -- was designed in collaboration with FDA (see BioCentury, Nov. 4).

An academic committee selected the first five compounds, which include rilotumumab ( AMG 102), a human mAb against human hepatocyte growth factor/ scatter factor ( HGF/SF) from Amgen Inc. (NASDAQ:AMGN); AZD4547, a fibroblast growth factor receptor ( FGFR) tyrosine kinase inhibitor from AstraZeneca plc (LSE:AZN; NYSE:AZN); MEDI4736, a human IgG1 mAb targeting programmed cell death 1 ligand 1 ( CD274 molecule; PD-L1; B7-H1) from AZN's MedImmune LLC; palbociclib ( PD-0332991), a cyclin dependent kinase 4 (CDK4) and CDK6 inhibitor from Pfizer Inc. (NYSE:PFE); and an inhibitor of phosphoinositide 3-kinase (PI3K) from the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY). Additional agents can be added in the future. ...